Introduction to Predicting Infliximab Nonresponse

Managing pediatric inflammatory bowel disease (IBD) often involves biologic therapies. However, predicting infliximab nonresponse remains a significant clinical challenge. Primary nonresponse (PNR) occurs when a patient fails to show clinical benefit shortly after starting treatment. Consequently, identifying these patients early can prevent unnecessary drug exposure and allow for faster drug sequencing. Recent research from the Canadian Children IBD Network has introduced a proteomics-based model to address this gap.

The Proteomics Model and Diagnostic Windows

Researchers evaluated a prospective cohort of 96 children with colonic IBD, including ulcerative colitis (UC) and Crohn’s disease (CD). Specifically, they measured serum proteins using Olink Inflammation and Immune Response panels. The study compared treatment-naïve serum with treatment-exposed serum to determine which was more predictive. Notably, the team used a regularized regression machine learning model to analyze the data. They found that treatment-naïve samples were significantly more informative for predicting infliximab nonresponse than those taken after drug exposure. Therefore, the diagnostic window before starting therapy appears to be the most critical time for biological assessment.

Key Findings and Protein Biomarkers

The machine learning model achieved an area under the curve (AUC) of approximately 0.75. This indicates a good ability to separate responders from nonresponders. Furthermore, the model identified 21 specific proteins that serve as predictive signatures. Among these, CSF1 and ITM2A emerged as the top-ranked features. Interestingly, serum infliximab levels themselves were similar between responders and nonresponders during the early maintenance phase. This suggests that PNR is likely driven by underlying biological pathways rather than rapid drug clearance alone. Additionally, UC and IBD-unclassified responders were more frequently steroid-refractory at the start of therapy.

Clinical Implications for Pediatric IBD

These findings suggest that a pre-treatment serum protein signature could help clinicians optimize therapy. While external validation is necessary, the results highlight the potential for personalized medicine in pediatric gastroenterology. By identifying nonresponders before the first dose, doctors can prioritize alternative biologics or small molecules. Consequently, this approach may improve long-term outcomes for children with severe colonic disease.

Frequently Asked Questions

What is primary nonresponse (PNR) in IBD?

PNR refers to the lack of clinical improvement following induction therapy with a biologic, typically leading to drug cessation or surgery within six months of initiation.

Why is treatment-naïve serum better for prediction?

The research indicates that the initial disease state before therapeutic intervention provides a clearer biological signal. Once a patient is exposed to infliximab, the drug alters the protein environment, which may obscure the primary failure mechanisms.

Which proteins were most important in the model?

The top-ranked proteins for predicting nonresponse were CSF1 (Colony Stimulating Factor 1) and ITM2A (Integral Membrane Protein 2A).

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Ricciuto A et al. Primary infliximab failure in pediatric colonic inflammatory bowel disease: Development of a proteomics predictive model using a prospective Canadian cohort. Inflamm Bowel Dis. 2026 Feb 11. doi: undefined. PMID: 41671043.